findmyKOL

Suresh Ramalingam, MBBS

Enriched profile

Executive Director, Winship Cancer Institute of Emory University; Professor and Roberto C. Goizueta Distinguished Chair for Cancer Research, Department of Hematology and Medical Oncology, Emory University School of Medicine · Winship Cancer Institute of Emory University

ORCID↗NPI↗
✓ Full profile
RegionAtlanta, GA · SoutheastSpecialtyMedical OncologyFocusLung Cancer Treatments and Mutations+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2014–2026

Suresh Ramalingam is Executive Director, Winship Cancer Institute of Emory University; Professor and Roberto C. Goizueta Distinguished Chair for Cancer Research, Department of Hematology and Medical Oncology, Emory University School of Medicine at Winship Cancer Institute of Emory University. OpenAlex indexes 1,240 publications with 106,346 citations (h-index 125); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Suresh Ramalingam as a Highly Cited Researcher (Clinical Medicine, 2020-2025; Cross-Field, 2019).

Data verified 24 Aug 2026

Overview

Updated 14 Oct 2026

Suresh S. Ramalingam is Executive Director, Winship Cancer Institute of Emory University. The public record shows 1,240 publications with 106,346 citations (h-index 125), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 14 registered clinical trials, 9 NIH-funded awards (2014–2026).

  • Most recent indexed publication: 2026 · JCO oncology practice
  • Top research focus: Lung Cancer Treatments and Mutations
  • 14 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)8 trialsSmall Cell Lung Carcinoma3 trialsSarcoma1 trialMesothelioma, Malignant1 trialMesothelioma1 trialComa1 trialLeukemia (AML/ALL/CML/CLL)1 trialLymphoma1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialLymphoma, Non-Hodgkin1 trialLeukemia, Lymphocytic, Chronic, B-Cell1 trialLymphoma, Follicular1 trialHodgkin Disease1 trialBurkitt Lymphoma1 trialLymphoma, B-Cell, Marginal Zone1 trialLymphoma, B-Cell1 trialWaldenstrom Macroglobulinemia1 trialMycosis Fungoides1 trialSezary Syndrome1 trialLymphoma, T-Cell1 trialIntraocular Lymphoma1 trialLeukemia, T-Cell1 trialGranuloma1 trialLymphomatoid Granulomatosis1 trialOvarian / Gynecologic Cancer1 trialHereditary Breast and Ovarian Cancer Syndrome1 trialCarcinoma, Small Cell1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Drugs & molecules

across trials, industry payments and publications
Tagrissogeneric · OsimertinibClinical trials1Industry payments8Publications22Opdivogeneric · NivolumabClinical trials—Industry payments1Publications8CarboplatinClinical trials3Industry payments—Publications1Imfinzigeneric · DurvalumabClinical trials—Industry payments1Publications3PemetrexedClinical trials1Industry payments—Publications3PembrolizumabClinical trials2Industry payments—Publications1DocetaxelClinical trials1Industry payments—Publications1VeliparibClinical trials1Industry payments—Publications1PaclitaxelClinical trials4Industry payments—Publications—EverolimusClinical trials2Industry payments—Publications—VorinostatClinical trials2Industry payments—Publications—Abivertinib MaleateClinical trials1Industry payments—Publications—

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trials—Industry payments10AstraZeneca Pharmaceuticals LPClinical trials—Industry payments9Daiichi Sankyo Inc.Clinical trials—Industry payments5National Cancer Institute (NCI)Clinical trials5Industry payments—Emory UniversityClinical trials4Industry payments—AstraZeneca UK LimitedClinical trials—Industry payments3GlaxoSmithKline, LLC.Clinical trials—Industry payments3AstraZenecaClinical trials2Industry payments—Genentech USA, Inc.Clinical trials—Industry payments2ACEA Therapeutics, Inc.Clinical trials1Industry payments—E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments1Eastern Cooperative Oncology GroupClinical trials1Industry payments—ECOG-ACRIN Cancer Research GroupClinical trials1Industry payments—Gilead Sciences, Inc.Clinical trials—Industry payments1Ipsen Biopharmaceuticals, IncClinical trials—Industry payments1Janssen Biotech, Inc.Clinical trials—Industry payments1Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,240publications

Distinct works indexed by OpenAlex, matched via ORCID; 65 in PubMed.

106,346citations

Total citations across indexed works.

125h-index

Hirsch index (OpenAlex). i10-index 481.

Clinical & industry

trials, payments and federal funding
14clinical trials

Investigator role on registered studies.

View trials ↓
11companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
9NIH grants · 2014–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:

All 14 trial records: search, sort and filter.Explore →

Industry payments

11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 17 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    61.7%
    Kinase inhibitor61.7%
    Tagrisso49%Retevmo22%Zykadia19%Tabrecta11%
    Part D<11 patients

  • Sensory organs

    19.7%
    Corticosteroid19.7%
    Dexamethasone100%
    Part D<11 patients

  • Metabolism & gastrointestinal

    13%
    Serotonin-3 Receptor Antagonist13%
    Ondansetron Hcl100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

9 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:

All 66 award records: search, sort and filter.Explore →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 65 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
    5,280 citations2017
    doi.org ↗
  2. 02
    Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
    3,332 citations2016
    doi.org ↗
  3. 03
    Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
    3,138 citations2018
    doi.org ↗
  4. 04
    Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
    2,838 citations2019
    doi.org ↗
  5. 05
    Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
    2,824 citations2019
    doi.org ↗
All 1,240 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Taofeek K. Owonikoko358Fadlo R. Khuri252Shi‐Yong Sun148Gabriel Sica124Madhusmita Behera121Chandra P. Belani118Walter J. Curran114Myung‐Ju Ahn104Rathi N. Pillai96Jhanelle E. Gray94Fumio Imamura85Vassiliki A. Papadimitrakopoulou84Ying Cheng84Xingming Deng84Zhengjia Chen83Isamu Okamoto83Conor Steuer82Byoung Chul Cho78Michael Boyer78Yi‐Long Wu77Nabil F. Saba74Julie R. Brahmer73Geoffrey R. Oxnard73Juliann Chmielecki73Rachel Hodge72J. Carl Barrett71Aleksandra Markovets71Frances A. Shepherd70Margarita Majem69Ryan J. Hartmaier68Kristin Higgins67Meng‐Chih Lin65Pasi A. Jänne65Astrid McKeown64Dong M. Shin63Oliver Gautschi63Krishna C. Bulusu62Haian Fu62Hossein Borghaei59Joan H. Schiller54

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/suresh-ramalingam-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/sureshramalingammd

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Suresh-S-Ramalingam-39843095

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/RamalingamMD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

Mentions by others

where others cite or feature them
  • Other

    time.com/collections/time100-health-2025/7279582/suresh-ramalingam

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →time.com ↗
  • Other

    onclive.com/authors/suresh-s-ramalingam-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • X / Twitter

    x.com/WinshipAtEmory/status/1920569717195985039

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • Spotify

    cancerletter.com/podcastc/20250214_5

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellowship

    Hematology & Oncology, University of Pittsburgh Medical Center

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
  • Board Certification: Medical Oncology

    American Board of Internal Medicine

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
  • Residency

    Internal Medicine, Wayne State University, 1996 (served as Chief Medical Resident)

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
  • Internship

    Internal Medicine, Wayne State University

    1994
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
  • MBBS

    Kilpauk Medical College

    1992
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗

Editorial & leadership roles

journal and society appointments
  • 2016-2017 Chair

    ASCO Professional Development Committee

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
  • Executive Director

    Winship Cancer Institute of Emory University

    2016
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.emory.edu ↗
  • Chair

    Thoracic Malignancies Committee, ECOG-ACRIN Cancer Research Group

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
  • Deputy Chair

    Therapeutics Programs, ECOG-ACRIN Cancer Research Group

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
  • Member

    Medical Oncology Board Exam Committee, American Board of Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
  • Past President

    Georgia Society of Clinical Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
  • Board Member

    Georgia CORE

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →winshipcancer.emory.edu ↗

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    202020212022202320242025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
  • Cross-Field
    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Assistant Dean for Cancer Research

    Emory University School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →whsc.emory.edu ↗
  • Director

    Division of Medical Oncology, Emory University School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →whsc.emory.edu ↗
  • Associate Vice President for Cancer

    Woodruff Health Sciences Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
  • Principal Investigator

    Winship Lung Cancer SPORE (NCI Specialized Program of Research Excellence)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →whsc.emory.edu ↗
  • Previously Assistant Professor

    University of Pittsburgh School of Medicine and Wayne State University

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →whsc.emory.edu ↗
  • Member

    IASLC (International Association for the Study of Lung Cancer) Board of Directors

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.